Stage III Bladder Cancer AJCC v8 Clinical Trials

18 clinical trials for Stage III Bladder Cancer AJCC v8 across international registries, including 4 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• Consolidative Therapy After EV + Pembrolizumab in Muscle Invasive Bladder Cancer, REINFORCE Trial — RECRUITING · PHASE1
• Enfortumab Vedotin Plus Pembrolizumab for the Treatment of Locally Advanced or Metastatic Bladder Cancer of Variant Histology — RECRUITING · PHASE2
• Enfortumab Vedotin and Pembrolizumab With Cystectomy and/or Ureterectomy for Locally Advanced or Metastatic Bladder and Upper Urothelial Tract Cancer, CAST-AI Trial — RECRUITING · PHASE4
• An Education and Navigation Support Tool to Improve Participation in Care Coordination Among Patients With Locally Advanced, Metastatic and Unresectable Bladder Cancer and Their Caregivers — RECRUITING · NA
• Testing the Addition of Tazemetostat to the Immunotherapy Drug, Pembrolizumab (MK-3475), in Advanced Urothelial Carcinoma — ACTIVE_NOT_RECRUITING · PHASE1
• Atezolizumab With or Without Eribulin Mesylate in Treating Patients With Recurrent Locally Advanced or Metastatic Urothelial Cancer — ACTIVE_NOT_RECRUITING · PHASE2
• Testing the Addition of the Anti-cancer Drug, Cabozantinib, to the Usual Immunotherapy Treatment, Avelumab, in Patients With Metastatic Urothelial Cancer, MAIN-CAV Study — ACTIVE_NOT_RECRUITING · PHASE3
• Testing Olaparib in Patients With Advanced or Metastatic (Cancer That Has Spread) Bladder Cancer and Other Genitourinary Tumors With DNA-Repair Genetic Changes — ACTIVE_NOT_RECRUITING · PHASE2
• A Study of Chemotherapy and Radiation Therapy Compared to Chemotherapy and Radiation Therapy Plus MEDI4736 (Durvalumab) Immunotherapy for Bladder Cancer Which Has Spread to the Lymph Nodes, INSPIRE Trial — ACTIVE_NOT_RECRUITING · PHASE2
• Cabozantinib S-malate and Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Genitourinary Tumors — ACTIVE_NOT_RECRUITING · PHASE1
• Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced Cancers After Progression on PD-1 or PD-L1 Targeted Antibodies — TERMINATED · PHASE1
• ARID1A and/or KDM6A Mutation and CXCL13 Expression — ACTIVE_NOT_RECRUITING · PHASE2
• Tocilizumab, Ipilimumab, and Nivolumab for the Treatment of Advanced Melanoma, Non-Small Cell Lung Cancer, or Urothelial Carcinoma — ACTIVE_NOT_RECRUITING · PHASE2
• Remote Telemonitoring of Patient-Generated Physiologic Health Data and Patient-Reported Outcomes — COMPLETED
• Testing Anti-Cancer Drugs Erdafitinib With or Without Atezolizumab in Patients With Localized Bladder Cancer Not Able to Receive Cisplatin Chemotherapy, NERA Trial — WITHDRAWN · PHASE2
• Atezolizumab and CYT107 in Treating Participants With Locally Advanced, Inoperable, or Metastatic Urothelial Carcinoma — COMPLETED · PHASE2
• Pembrolizumab in Treating Patients With Bladder Cancer Undergoing Radical Cystectomy — COMPLETED · PHASE2
• Avelumab in Combination With Fluorouracil and Mitomycin or Cisplatin and Radiation Therapy in Treating Participants With Muscle-Invasive Bladder Cancer — COMPLETED · PHASE2

Refine this search